In a phase 2 extension study of Parkinson's disease-related dementia, blarcamesine was deemed safe and effective.

Published Date: 06 Apr 2023

The COVID-19 pandemic forced a halt to the trial, but patients who chose to continue their medication into the open-label extension showed marked improvements in their Parkinson disease dementia symptoms for up to 48 weeks.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Short Shrift in Cancer Funding; Bypassing Familiar for Distant; Testing for BRCA.

2.

Pre-operative evaluation of ovarian cancer patients using DWI-MRI is helpful.

3.

Rural colon cancer patients face higher risks, but minimally invasive surgery could narrow gap

4.

Novel topical fluorescent imaging technique rapidly and safely detects basal cell carcinoma

5.

Potential new therapy for childhood brain cancer could heal treatment-resistant tumors


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot